Abstract. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated mortalities worldwide. The role of ornithine transcarbamylase (OTC) in HCC remains unclear. In the present study, the expression of OTC in HCC was analyzed based on datasets from the Gene Expression Omnibus database of the National Center for Biotechnology Information and further confirmed by immunohistochemistry, western blotting analysis and reverse transcription-quantitative polymerase chain reaction assays on clinical samples and cell lines. Furthermore, the associations between OTC expression and clinicopathological parameters as well as clinical outcome, including the overall and disease-free survival rates were analyzed. Finally, the effect of OTC on HCC cells was measured using proliferation, bromodeoxyuridine and colony-formation assays. Lower OTC expression was observed in HCC cells and tissues compared with primary human hepatocytes. Further investigation demonstrated that low expression of OTC in HCC was associated with larger tumor size and advanced grade. A Kaplan-Meier analysis revealed that patients with lower levels of OTC exhibited shorter overall and disease-free survival times. Notably, OTC silencing with RNA interference facilitated cell proliferation in HCC SK-Hep-1 and Huh-7 cells. However, overexpression of OTC led to inhibition of cell proliferation. In conclusion, the present study identified a novel role of OTC in HCC development, providing a potential novel therapeutic target for this disease.
Introduction
Hepatocellular carcinoma (HCC) accounts for 70-90% of primary liver cancer, as estimated in 2012 (1), with >500,000 patients worldwide being diagnosed with hepatocellular carcinoma, as estimated in 2011 (2) . Liver cancer has been predicted to be the sixth most commonly diagnosed type of cancer and the fourth leading cause of cancer-associated mortality worldwide in 2018, with ~841,000 new cases and 782,000 cases of cancer-associated mortality annually (3) . Apart from surgery, multiple treatment options are available for HCC treatment, including resection, ablation, transplantation, chemoembolization and systemic targeted agents, such as sorafenib (4) . However, resistance to chemotherapeutic drugs, cancer recurrence and early metastasis remain major obstacles in clinical treatment (5) . Therefore, improved understanding of the molecular mechanisms in HCC is required.
Ornithine transcarbamylase (OTC) is a liver and intestinal mucosa-located, intramitochondrial, rate-limiting enzyme in the urea cycle. It catalyzes the reaction that converts ornithine and carbamoyl phosphate into citrulline, which is the second step of the urea cycle, to detoxify the ammonia produced from amino acid catabolism (6) . Defects in the urea cycle can lead to high blood ammonia concentration, which can cause several physiological disorders, including anorexia, cerebral edema, coma, seizure, delayed growth and development, intellectual disabilities and even loss of life (7, 8) . Several studies have suggested that accumulated ammonia resulting from OTC deficiency causes chronic liver damage, which is a potential risk factor of HCC (9) (10) (11) . Furthermore, increased liver fibrosis in OTC-knockout Het mice compared with their wild-type littermates has been confirmed (12) . However, studies on the effect of OTC in HCC are limited.
The present study aimed to identify whether OTC serves a role in HCC progression, and to investigate its biological function. The present study revealed that OTC downregulation is a characteristic molecular alteration and a reliable prognostic factor for the survival of patients with HCC. Notably, the present study demonstrated anti-growth effects of OTC in HCC cells for the first time. The present study suggested that OTC may be investigated as a novel HCC therapeutic. Cell transfection. All siRNAs and plasmids were transfected into cells using Lipofectamine ® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Specifically, cells were seeded into 6-well-plates the day before transfection and were grown to 70-90% confluency prior to transfection. For OTC knockdown analysis, 0.1 nmol siOTC-1 or siOTC-2, or siCont (final concentration, 50 µM) and Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) were mixed and incubated for 10 min, and subsequently added to SK-Hep-1 and Huh-7 cells. For OTC overexpression analysis, 2 µg plasmids (pCMV6-XL4-OTC or pCMV6-XL4), Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) and Lipofectamine ® 3000 were mixed and incubated for 10 min, and then added to SK-Hep-1 and Huh-7 cells. After 6 h of incubation, the supernatant was replaced with fresh medium. The transfection efficiency was monitored by western blot analysis after 3 days of transfection. The bromodeoxyuridine assays were conducted 3 days after transfection. For the colony formation assay, colonies were stained 12 days after transfection. For the proliferation assay, cell numbers were counted daily between the second and fifth day after transfection. Datasets. Gene expression profiles were downloaded using R version 3.2.4 software (R Foundation for Statistical Computing, Vienna, Austria) from the Gene Expression Omnibus database (dataset accession no. GSE14520) (15) . RNA-sequencing and detailed clinicopathological data for patients with HCC were obtained from The Cancer Genome Atlas (TCGA; project ID: TCGA-LIHC; https://portal.gdc. cancer.gov/projects/TCGA-LIHC). The data from TCGA were log 10 transformed and analyzed using SPSS version 19.0 software (IBM Corporation, Chicago, IL, USA).
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Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA of all cell lines and liver tissues collected in the present study was extracted using TRIzol reagent (Tiangen Biotech Co., Ltd., Beijing, China). cDNA was synthesized from 1 µg total RNA using an FastQuant RT kit (Tiangen Biotech Co., Ltd.), according to the manufacturer's protocol. qPCR was conducted using a CFX Connect Real-Time system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Thermocycling conditions were as follows: Initial denaturation at 95˚C for 2 min, and 20 sec denaturing at 94˚C, 20 sec annealing at 60˚C and 20 sec extension at 72˚C for 35 cycles, followed by 0.5˚C every 5 sec from 65 to 95˚C for melting curve analysis. FastStart Universal SYBR Green Master Mix (Roche Diagnostics, Indianapolis, IN, USA) was used. The sequences of primers were as follows: OTC forward, 5'-TGG CTG ATT ACC TCA CGC TC-3' and reverse, 5'-TTC TTC TGG CTT TCT GGG CAA-3'; β-actin forward, 5'-CTC TTC CAG CCT TCC TTC CT-3' and reverse, 5'-AGC ACT GTG TTG GCG TAC AG-3'. The experiments were performed 3 times. The relative OTC mRNA expression levels were determined with β-actin as an endogenous control, using the 2 -ΔΔCq method (16) .
Western blot analysis. The cells were harvested and lysed with radioimmunoprecipitation assay lysis buffer supplemented with a protease inhibitor cocktail (Roche Diagnostics). Protein quantification was conducted using the BCA assay (Pierce; Thermo Fisher Scientific, Inc.). Total proteins (30 µg/lane) were separated using 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (GE Healthcare Life Sciences, Little Chalfont, UK). The membranes were blocked with 5% skimmed milk for 1 h at room temperature, and incubated with OTC primary antibody (1:1,000 dilution) or GAPDH (1:5,000 dilution) primary antibody at 4˚C overnight. They were subsequently incubated with horseradish peroxidase-conjugated anti-rabbit (1:3,000 dilution; cat. no. NA934; GE Healthcare Life Sciences) or anti-mouse IgG secondary antibodies (1:5,000 dilution; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h. The blots were developed with ECL western blotting analysis reagents (Merck KGaA) and the signal intensities were quantified using ImageJ version 1.4 software (National Institutes of Health, Bethesda, MD, USA). , Santa Clara, CA, USA). Counterstaining was performed using hematoxylin for 2 min at room temperature. Negative control sections were prepared without primary antibody to determine the specificity of the staining. The scoring of OTC was carried out by two independent pathologists using a light microscope, according to the proportion of tumor cells with positive staining (negative, none; weak, <10%; moderate, 10-50%; strong, >50%), as previously described (17) . No and weak staining were defined as OTC negative, and moderate and strong staining were defined as OTC positive. Images were captured using an Olympus microscope equipped with a Olympus DP71 digital camera (magnification, x200; Olympus Corporation, Tokyo, Japan).
Immunohistochemistry (IHC
Proliferation and bromodeoxyuridine assays. Cell proliferation in response to OTC silencing or overexpression was determined by a trypan blue exclusion assay (Thermo Fisher Scientific, Inc.). DNA synthesis was examined using a Click-iT ® EdU Imaging kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols.
Colony-formation assay. Cells transfected with plasmids (pCMV6-XL4-OTC and pCMV6-XL4) and siRNAs (siOTC-1, siOTC-2 and siCont) were re-seeded in 12-well plates and incubated at 37˚C for 12 days, with the medium being changed every 3 days. Images and metrics of newly formed colonies were obtained by using IncuCyte ® (model: CCL-170T-8; Essen Bioscience, Ann Arbor, MI, USA). Each experiment was repeated independently 3 times.
Statistical analysis. The difference between two groups was assessed using two-tailed Student's t-test. OTC expression in HCC and adjacent non-tumor liver tissue samples was compared using paired two-tailed Student's t-test. Differences in OTC positive rates between HCC and adjacent non-tumor liver tissues, as examined by IHC, were evaluated by Fisher's exact test. One-way analysis of variance followed by Dunnet's post hoc test was performed for comparisons among multiple groups. Associations between OTC expression and clinicopathological parameters were evaluated using a nonparametric χ 2 test. The survival rate analysis was performed using the Kaplan-Meier method and equivalences of the survival curves were tested using log-rank statistics. All statistical analyses were performed using SPSS version 19.0 software. Differences were considered statistically significant when P<0.05. P<0.01 and *** determined using RT-qPCR and western blot analyses. The RT-qPCR analysis revealed that OTC mRNA expression was significantly lower in the liver cancer cells compared with that in PHHs (Fig. 1B) . In addition, the OTC protein levels were lower in the liver cancer cell lines compared with those in PHHs, as detected by western blotting (Fig. 1C) . Similar to HCC cells, MIHA cells exhibited lower OTC expression compared with PHH cells. As numerous genes identified to be dysregulated were associated with cell immortalization and transformation (18, 19) , it is possible that immortalization contributed to the downregulation of OTC in MIHA cells.
Results
OTC expression is
Subsequently, OTC protein expression was investigated in 15 HCC tissue samples obtained from the Pathology Department of First Affiliated Hospital, Chongqing Medical University and their respective adjacent non-tumor liver samples via IHC (Fig. 1D) . The findings revealed that, in the 15 cases examined, all the adjacent non-tumor liver tissues exhibited positive (strong or moderate) OTC expression. However, positive expression was detected in only 4 of the 15 HCC tissues (26.7%) ( Table SI) The association between OTC expression and clinicopathological parameters. The association between OTC expression and the clinicopathological features of the patients with HCC was examined in the 42 cases included in this study. The patients were classified into two groups based on the OTC protein level (cases where the protein level in the tumor tissue relative to the adjacent non-tumor tissue sample was <1.0 were classified as low-expression; the rest were classified as high-expression). The findings revealed low expression in 30 of the 42 cases (71.4%) and high expression in 12 cases (28.6%) ( Table I ). Pearson's χ 2 test revealed that lower tumor OTC levels were associated with a larger tumor size (P=0.01) and higher grade (P=0.02). No significant association was observed between OTC levels and patient age or sex, or other clinical parameters, including cirrhosis, vascular invasion, multiple tumors and the serological predictor of liver damage, alanine aminotransferase. In addition, the tumor OTC levels were evaluated according to the tumor stage in data obtained from the TCGA database (http//gdc.cancer.gov/). As demonstrated in Fig. 2A , the OTC mRNA levels in patients with early stage tumors (stage I) was higher than those with stage II (P=0.0029) or III (P=0.0002) tumors. To further confirm that low OTC levels indicate poor HCC prognosis, the 5-year overall survival times of 373 HCC cases and disease-free survival times of 313 cases from TCGA database were analyzed using the Kaplan-Meier method.
Patients with low OTC expression exhibited significantly shorter disease-free survival (P=0.0044; Fig. 2B ) and 5-year overall survival rates (P=0.0197; Fig. 2C ) compared with those with high expression. Together, these results demonstrate that low OTC levels are associated with tumor progression and poor survival rates, making this factor a potential novel biomarker for patients with HCC.
OTC overexpression inhibits HCC cell proliferation. To explore the functional role of OTC in HCC, OTC was overexpressed in Huh-7 and SK-Hep-1 cells by transient transfection and verified by western blotting (Fig. 3A) . The effects of OTC overexpression on the cells were assessed by cell proliferation and colony-formation assays. The upregulation of OTC significantly decreased the proliferation rates of Huh-7 and SK-Hep-1 cells (Fig. 3B and C) . Furthermore, decreased numbers and sizes of SK-Hep-1 and Huh-7 cell colonies were observed in the OTC overexpression groups compared with the control groups, which were transfected with vector plasmid (Fig. 3D) . Finally, OTC overexpression led to an inhibition of DNA synthesis, as revealed by EdU staining (Fig. 3E and F) . Collectively, these results demonstrate that OTC overexpression serves an inhibitory role in cell proliferation and colony-formation in HCC cells. The cells were transfected with the OTC expression plasmid (pCMV6-XL4-OTC) or the corresponding empty vector (pCMV6-XL4) and harvested 3 days after transfection. Upregulated OTC led to an inhibited proliferation rate in (B) SK-Hep-1 and (C) Huh-7 cells. The cells were counted at the indicated time points using a trypan blue exclusion assay. The data are presented as the mean ± standard deviation of 3 independent experiments and the groups were compared using two-way analysis of variance. * P<0.05. (D) OTC overexpression resulted in inhibited colony formation. SK-Hep-1 and Huh-7 cells transfected with the OTC expression plasmid or the corresponding empty vector were cultured for 12 days, images were captured, and newly formed colonies in each well were counted and expressed as a percentage relative to the control group. The data are presented as the mean ± standard deviation of 3 independent experiments, and the groups were compared using two-tailed unpaired Student's t-test. ** P<0.01. DNA synthesis in (E) SK-Hep-1 and (F) Huh-7 cells was determined 3 days after transfection. Original magnification, x400. The quantification of EdU-positive cells was conducted macroscopically and expressed as a percentage relative to the control group. The data are presented as the mean ± standard deviation of 3 independent experiments and the groups were compared using two-tailed unpaired Student's t-test. OTC silencing facilitates HCC cell proliferation. To further evaluate the biological effects of OTC on HCC cells, an RNA interference experiment was performed on Huh-7 and SK-Hep-1 cells. Targeting siRNAs (siOTC-1 and siOTC-2) suppressed OTC expression, as determined by western blotting (Fig. 4A) . OTC downregulation significantly enhanced cell proliferation in the two cell lines (Fig. 4B and C) , and resulted in enhanced colony-formation ability (Fig. 4D) . In addition, elevated DNA synthesis was observed in OTC-knockdown cells ( Fig. 4E and F) . Together, these data support that OTC downregulation promotes HCC cell proliferation and colony formation.
Discussion
OTC, a key enzyme in the urea cycle, has been well documented in ammonia metabolism (20) . However, few studies have focused on the role of OTC in HCC. A previous study demonstrated that OTC deficiency could increase the risk of developing HCC, suggesting that OTC may be associated with HCC progression. Another study revealed that OTC depletion could increase the probability of liver fibrosis in a mouse model, and since ~90% of HCC develops from liver fibrosis, this suggests that OTC is indirectly linked to HCC progression (11, 12) . However, direct evidence on the role of OTC in HCC progression is lacking. In the present study, the functional role of OTC in HCC was investigated. Based on the database analyses, OTC expression levels were revealed to be downregulated in HCC. This was further verified in liver cancer cell lines and 42 paired clinical HCC tissue samples. In agreement with the present findings, Liu et al (21) noticed that OTC mRNA levels are downregulated in HCC Huh-7 and LH86 cell lines. To further elucidate the role of OTC in HCC, associations between OTC expression and the clinicopathological features of the patients were investigated. The results demonstrated that low OTC expression was associated with larger tumor size and advanced grade. Furthermore, low tumor OTC expression indicated poor prognosis for patients with HCC.
The enzyme activity of OTC is inhibited by acetylation at lysine 88, highlighting the important role of a deacetylase in the regulation of its function (6) . Furthermore, the mitochondrial NAD-dependent protein deacetylase sirtuin-3 (SIRT3) has been identified as a regulator of OTC deacetylation (22) . Notably, a previous study determined that SIRT3 is downregulated in HCC cells, possibly protecting them from apoptosis (23) . Combined with the present observations that OTC functions as a tumor suppressor, it was hypothesized that the acetylation of OTC in HCC cells is increased by the downregulation of SIRT3, leading to the suppression of its activity. This may explain the finding that OTC RNA interference promoted cell proliferation, whereas overexpression had the opposite effect in the present study.
It is worth noting that decreased OTC levels may impair the normal urea cycle, resulting in the accumulation of ammonia and a hyperammonemic state. High concentrations of ammonia in cells are toxic and induce cell apoptosis (24) (25) (26) (27) . This is contradictory to the observation that low OTC promoted HCC cell proliferation. In the present study, no clinical symptoms of hyperammonemia nor marked elevations of blood ammonia levels were observed in the patients with HCC. As glutamine metabolism is the main source of ammonia, it is hypothesized that HCC cells may utilize glutamine mainly through the transamination pathway without resulting in ammonia production. This non-canonical pathway of glutamine utilization is also observed in human pancreatic ductal adenocarcinoma cells, and it is required for tumor growth (28) . The implicated interactions between the transamination and amino acid metabolism pathways in HCC cells may be involved in the development of HCC mediated by downregulated OTC. Additionally, studies have reported that OTC may influence liver regeneration though participating in certain unidentified signaling pathways, independent of its known enzyme activity (29) . Further investigations are required to explain whether the effect of OTC on HCC cells relies on the protein itself or its catalytic properties and possible targets.
In summary, the present study revealed a new function of OTC in HCC tumorigenesis and progression. The decreased OTC levels may contribute to the HCC development of this disease, making it a potential target for therapy. Further studies are required to uncover the underlying mechanism involving OTC in the inhibition of HCC development.
